Alimu Dayimu

Robinson Way
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy.

Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 19, 2026

Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts.

Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts.

Journal: Cell reports. Medicine

Published: December 23, 2025

Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 22, 2025

Social environments and lifestyles linked to mortality and future health risks in metabolic syndrome: evidence from UK and US nationwide cohort studies.

Social environments and lifestyles linked to mortality and future health risks in metabolic syndrome: evidence from UK and US nationwide cohort studies.

Journal: BMJ public health

Published: November 24, 2025

Photoreceptor Layer Thinning as Biomarker for Circulatory Premature Mortality: UK Biobank Cohort Study.

Photoreceptor Layer Thinning as Biomarker for Circulatory Premature Mortality: UK Biobank Cohort Study.

Journal: Translational vision science & technology

Published: August 05, 2025

Identifying modifiable factors and their joint associations on late-onset schizophrenia risk in the UK Biobank: a prospective exposure-wide association study.

Identifying modifiable factors and their joint associations on late-onset schizophrenia risk in the UK Biobank: a prospective exposure-wide association study.

Journal: BMJ mental health

Published: July 16, 2025

Seamless monotherapy-combination phase I dose-escalation model-based design.

Seamless monotherapy-combination phase I dose-escalation model-based design.

Journal: Clinical trials (London, England)

Published: July 12, 2025

Survivorship of modern total hip replacement to 30 years: systematic review, meta-analysis, and extrapolation of global joint registry data.

Survivorship of modern total hip replacement to 30 years: systematic review, meta-analysis, and extrapolation of global joint registry data.

Journal: Lancet (London, England)

Published: May 09, 2025

Survivorship of modern total hip replacement to 30 years: systematic review, meta-analysis, and extrapolation of global joint registry data.

Survivorship of modern total hip replacement to 30 years: systematic review, meta-analysis, and extrapolation of global joint registry data.

Journal: Lancet (London, England)

Published: May 09, 2025

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.

Journal: Nature cancer

Published: February 11, 2025

A Trial of Semicircular Canal Plugging vs. Intratympanic Gentamicin for Menière's Disease.

A Trial of Semicircular Canal Plugging vs. Intratympanic Gentamicin for Menière's Disease.

Journal: The Laryngoscope

Published: February 05, 2025

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

Journal: Nature communications

Published: October 25, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026